Author Login

Correspondence to Author: Délio Tiago Martins Malaquias^1-7,Pietra Kananovicz Fernandes¹, Riala Caroline Cheloni Catarino¹Rafaela Gonçalves Bueno¹,Giulia Bortoloni Agria¹, José Carlos Ferreira da Silva¹, Aghata Abreu Mendes Faria¹, Adriana F. Viana Delgado¹, Erica Miriam Fernandes Miranda Vão¹, Raquel Perez Carvalho¹, Giovana Casarini Yamashiro², Luiza Benicio Teodoro², Beatriz Randone Pereira², Guilherme Pio Vilela², Jaqueline de Carvalho Ferreira², Guilherme Kovacsik Carvalho Balzano⁴, Rubens Rodrigues Tudela⁵, Thiago Augusto Rochetti Bezerra⁶, Joel Eloi Belo Junior⁷. 

1. Medical student. University of Ribeirão Preto, Guarujá, São Paulo.
2. Medical student. Nove de Julho University, São Bernardo do Campo, São Paulo, Brazil.
3. Physician graduated from the Nove de Julho University in São Bernardo do Campo, São Paulo, Brazil.
4. Medical student. São Judas. Cubatão, São Paulo, Brazil.
5. PhD in Medical Sciences. Ribeirão Preto Medical School. University of São Paulo. Ribeirão Preto-SP.
6. Physiotherapist graduated from the University of Mogi das Cruzes, São Paulo-SP, Postgraduate in Hospital Physiotherapy, Bahiana School
of Medicine and Public Health, Salvador -BA; Postgraduate in Respiratory Physiotherapy and Intensive Care in Pediatrics and Neonatology, University of São Paulo - São Paulo-SP.
7. Master’s Degree in Operational Human Performance.Master’s Degree in Intellectual Property and Technology Transfer for Innovation.

DOI: 10.52338/jodr.2025.4833

Abstract:

Tirzepatide (Mounjaro), a dual GLP-1 and GIP receptor agonist, has emerged as one of the most promising therapies for metabolic control in patients with obesity and type 2 diabetes mellitus (DM2). This systematic review aimed to evaluate the clinical efficacy and safety of tirzepatide, with a focus on reducing glycated hemoglobin (HbA1c), weight loss and cardiovascular impact. Five randomized clinical trials published between 2020 and 2023 were included. The results showed that tirzepatide promoted HbA1c reductions of between 1.8% and 2.4%, and body weight losses of up to 20.9%, being superior to other incretin-based therapies, such as semaglutide and liraglutide. In addition, three of the five included studies showed a reduction in cardiovascular events, especially in patients with DM2 and high CV risk. Tirzepatide showed a favorable safety profile, with predominantly gastrointestinal adverse effects and a low incidence of hypoglycemia. The weekly dosage and multifactorial effect make this drug an attractive option for integrated metabolic management. However, limitations such as high cost and lack of data in special populations should be considered. It is concluded that tirzepatide represents a relevant therapeutic advance, with the potential to change clinical guidelines in the treatment of obesity and DM2.

Keywords:tirzepatida, GLP-1, GIP, type 2 diabetes, obesity, glycemic control, weight loss, cardiovascular events.

Citation:

Dr. Thiago Augusto Rochetti Bezerra. Use of Tirzepatida (Mounjaro) as a Therapeutic Agent in Obesity and Type 2 Diabetes: A Systematic Review on Metabolic Control with GLP-1 Agonists. Journal of Diabetology Research 2025.